JP2021505604A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505604A5 JP2021505604A5 JP2020531041A JP2020531041A JP2021505604A5 JP 2021505604 A5 JP2021505604 A5 JP 2021505604A5 JP 2020531041 A JP2020531041 A JP 2020531041A JP 2020531041 A JP2020531041 A JP 2020531041A JP 2021505604 A5 JP2021505604 A5 JP 2021505604A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- immunotherapy
- composition
- cells
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000190A JP2024028380A (ja) | 2017-12-07 | 2024-01-04 | ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17205922.2 | 2017-12-07 | ||
| EP17205922 | 2017-12-07 | ||
| PCT/EP2018/084018 WO2019110815A1 (en) | 2017-12-07 | 2018-12-07 | Control and modulation of the function of gene-modified chimeric antigen receptor t cells with dasatinib and other tyrosine kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000190A Division JP2024028380A (ja) | 2017-12-07 | 2024-01-04 | ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021505604A JP2021505604A (ja) | 2021-02-18 |
| JP2021505604A5 true JP2021505604A5 (https=) | 2022-01-11 |
Family
ID=60629513
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531041A Pending JP2021505604A (ja) | 2017-12-07 | 2018-12-07 | ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節 |
| JP2024000190A Pending JP2024028380A (ja) | 2017-12-07 | 2024-01-04 | ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000190A Pending JP2024028380A (ja) | 2017-12-07 | 2024-01-04 | ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20210169880A1 (https=) |
| EP (1) | EP3720477A1 (https=) |
| JP (2) | JP2021505604A (https=) |
| CN (1) | CN111699001A (https=) |
| CA (1) | CA3084873A1 (https=) |
| WO (1) | WO2019110815A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018183888A2 (en) * | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
| KR20210135255A (ko) * | 2019-03-01 | 2021-11-12 | 내셔널 유니버시티 오브 싱가포르 | 조작된 면역 세포 |
| BR112022001418A2 (pt) * | 2019-08-08 | 2022-06-07 | Rigel Pharmaceuticals Inc | Compostos e método para tratar a síndrome de liberação de citocinas |
| CN112480263A (zh) * | 2019-09-12 | 2021-03-12 | 普米斯生物技术(苏州)有限公司 | 一种双特异t细胞激活器活化t细胞的设计及其应用 |
| CN111892661B (zh) * | 2020-08-12 | 2021-05-14 | 浙江康佰裕生物科技有限公司 | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 |
| CN116322691A (zh) * | 2020-09-24 | 2023-06-23 | 豪夫迈·罗氏有限公司 | T细胞双特异性抗体相关不良反应的预防或减轻 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| CN115348870B (zh) * | 2021-03-16 | 2023-06-13 | 上海驯鹿生物技术有限公司 | 通用型嵌合抗原受体t细胞及其应用 |
| WO2022210487A1 (ja) * | 2021-03-29 | 2022-10-06 | タカラバイオ株式会社 | 抗原に特異的な受容体を発現する免疫細胞の製造方法 |
| EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
| CN113699107B (zh) * | 2021-10-27 | 2022-02-01 | 东莞再立健生物科技有限公司 | 一种外周血nkt细胞培养液及培养方法 |
| CN116121196B (zh) * | 2022-12-23 | 2025-07-22 | 广州安捷生物医学技术有限公司 | 一种调控car-t细胞的方法与应用 |
| CN121574919A (zh) * | 2024-06-19 | 2026-02-27 | 徐州医科大学 | 一种诱导或富集Tscm或Tcm细胞的方法及其应用 |
| CN119060951B (zh) * | 2024-11-05 | 2025-02-14 | 星奕昂(上海)生物科技有限公司 | 一种高密度培养条件下提高nk细胞活率的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011034919A2 (en) * | 2009-09-15 | 2011-03-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| WO2018183888A2 (en) * | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
-
2018
- 2018-12-07 CN CN201880088946.4A patent/CN111699001A/zh active Pending
- 2018-12-07 CA CA3084873A patent/CA3084873A1/en active Pending
- 2018-12-07 EP EP18811588.5A patent/EP3720477A1/en active Pending
- 2018-12-07 WO PCT/EP2018/084018 patent/WO2019110815A1/en not_active Ceased
- 2018-12-07 JP JP2020531041A patent/JP2021505604A/ja active Pending
- 2018-12-07 US US16/767,545 patent/US20210169880A1/en not_active Abandoned
-
2022
- 2022-11-23 US US18/058,347 patent/US20230310432A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000190A patent/JP2024028380A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505604A5 (https=) | ||
| Zebley et al. | T cell dysfunction and therapeutic intervention in cancer | |
| JP7317793B2 (ja) | 改変γδＴ細胞 | |
| Shin et al. | NK cell-based immunotherapies in cancer | |
| Turtle et al. | CD19‐Targeted chimeric antigen receptor‐modified T‐cell immunotherapy for B‐cell malignancies | |
| Kim et al. | Glucocorticoid-induced tumor necrosis factor receptor–related protein co-stimulation facilitates tumor regression by inducing IL-9–producing helper T cells | |
| Coe et al. | Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy | |
| Alfarra et al. | Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy | |
| Dai et al. | Chimeric antigen receptors modified T-cells for cancer therapy | |
| Perna et al. | Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition | |
| JP2024028380A (ja) | ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節 | |
| Shook et al. | Natural killer cell engineering for cellular therapy of cancer | |
| JP2020517259A5 (https=) | ||
| CA2983434C (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same | |
| JP2017531687A5 (https=) | ||
| JP7467414B2 (ja) | 改良したｔ細胞治療方法 | |
| Velasquez et al. | CD28 and 41BB costimulation enhances the effector function of CD19-specific engager T cells | |
| Kintz et al. | Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma | |
| Tanaka et al. | Development of engineered T cells expressing a chimeric CD16-CD3ζ receptor to improve the clinical efficacy of mogamulizumab therapy against adult T-cell leukemia | |
| Johnson et al. | Effector CD8+ T-cell engraftment and antitumor immunity in lymphodepleted hosts is IL7Rα dependent | |
| Oliveira et al. | Sub‐optimal CD4+ T‐cell activation triggers autonomous TGF‐β‐dependent conversion to Foxp3+ regulatory T cells | |
| Giraudo et al. | Chimeric antigen receptor (CAR)-T cell therapy for non-Hodgkin's lymphoma | |
| Houtenbos et al. | Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting | |
| Vallet et al. | Adoptive cell therapy in multiple myeloma | |
| Roeven et al. | Immunotherapeutic approaches to treat multiple myeloma |